Effect of Anagliptin and Sitagliptin on Low-density Lipoprotein Cholesterol in Patients With Type 2 Diabetes and Cardiovascular Risk Factors: Randomized Controlled Trial
Phase of Trial: Phase IV
Latest Information Update: 07 Jun 2016
At a glance
- Drugs Anagliptin (Primary) ; Sitagliptin (Primary)
- Indications Coronary artery disease; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms REASON
- 07 Jun 2017 Biomarkers information updated
- 26 May 2016 Planned End Date changed from 1 Mar 2018 to 1 Dec 2018.
- 26 May 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Oct 2017.